ClinicalTrials.gg
Not yet recruitingNCT07581418Updated May 12, 2026

Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

An interventional study of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis, sponsored by Pak Emirates Military Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Pak Emirates Military Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing methotrexate in Psoriasis — 8 open to participants now, 8 under way, none of them phase 3. Methotrexate · Psoriasis.

Planned enrollment
11th of 31
88 · median 60
Started
2026
with 2 others
No phase
4 of 31
4 open now
Registered
30th of 31
by date

Among the 31 studies testing methotrexate in Psoriasis, this one is the 11th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 with no phase, and was the 30th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 31 studies testing methotrexate in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing methotrexate in Psoriasis, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the efficacy and safety of oral methotrexate and tofacitinib in patients with chronic plaque psoriasis. Participants diagnosed with chronic plaque psoriasis will be randomly assigned to receive either methotrexate or tofacitinib and will be followed for six months. Clinical improvement, disease severity, treatment response, and adverse effects will be assessed and compared between the two treatment groups.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Chronic Plaque Psoriasis
  • Methotrexate
  • Tofacitinib
  • Randomized Controlled Trial
  • Systemic Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants will comprise adults aged 18 to 70 years, of either gender, with moderate to severe plaque psoriasis defined by a Psoriasis Area and Severity Index (PASI) score greater than 10. A minimum disease duration of 6 months will be required. In addition, enrolment will be limited to patients whose psoriasis has shown inadequate response to at least one topical therapy despite a treatment duration of at least 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Participants with non-plaque variants of psoriasis or any other dermatological condition that could confound the assessment of psoriasis severity. Recent exposure to anti psoriatic therapy including systemic or biologic treatment within the preceding 4 weeks or topical treatment within the preceding 2 weeks. Individuals with known to, or for, either methotrexate or tofacitinib. Patients with a history of significant hepatic, renal, hematologic, gastrointestinal, or immune system disorders. Pregnant or breastfeeding women. Patients unavoidable prolonged sun or ultraviolet exposure. Patients with a history of alcohol abuse, or other conditions that contraindicate methotrexate use..
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Methotrexate group

    Participants in this group will receive oral methotrexate according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.

    Drug: Methotrexate

  • Active comparator
    Tofacitinib Group

    Participants in this group will receive oral tofacitinib according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

    Drug: Tofacitinib

Interventions

  • Oral methotrexate administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks.

  • Oral tofacitinib administered according to standard treatment protocol for chronic plaque psoriasis for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change in Psoriasis Area and Severity Index (PASI) score

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 6 months is below that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 12, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07581418
Lead sponsor
Pak Emirates Military Hospital
Responsible party
Aimen Umar Luk (Resident Dermatology, Pak Emirates Military Hospital) — Principal investigator
First posted
May 12, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Aimen Luk
Contact
aimanluk0915@gmail.com
+923215476167

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tofacitinib

Start the discussion